ExpreS2ion Biotechnologies Announces Research License Agreement with the University of Pennsylvania
Horsholm, Denmark, November 8, 2017 – Today, ExpreS2ion Biotechnologies ApS (“ExpreS2ion”), a fully owned subsidiary of ExpreS2ion Biotech Holding AB, announces that University of Pennsylvania, Philadelphia, USA, has signed a Research License Agreement granting University of Pennsylvania the right to conduct research using ExpreS2ion’s proprietary protein expression system, ExpreS2.The Research License Agreement The Research License Agreement grants University of Pennsylvania, Philadelphia, USA, the right to conduct research using ExpreS2ion’s proprietary ExpreS2 system for one year.